Yazaki, Shu
Shimoi, Tatsunori http://orcid.org/0000-0002-3603-8575
Yoshida, Masayuki
Sumiyoshi-Okuma, Hitomi
Arakaki, Motoko
Saito, Ayumi
Kita, Shosuke
Yamamoto, Kasumi
Kojima, Yuki
Nishikawa, Tadaaki
Tanioka, Maki
Sudo, Kazuki
Noguchi, Emi
Murata, Takeshi
Shiino, Sho
Takayama, Shin
Suto, Akihiko
Ohe, Yuichiro
Fujiwara, Yasuhiro
Yonemori, Kan
Funding for this research was provided by:
Jikei University School of Medicine
Article History
Received: 11 August 2022
Accepted: 25 October 2022
First Online: 16 November 2022
Declarations
:
: Tadaaki Nishikawa reports personal fees from Takeda Pharmaceutical Company, EISAI, and AstraZeneca, outside the submitted work. Emi Noguchi reports personal fees from Pfizer, Taiho, Eli Lilly, AstraZeneca, Chugai, and EISAI, outside the submitted work. Yuichiro Ohe reports grants and personal fees from AstraZeneca, Amgen, Bristol-Myers Squibb, Chugai, Eli Lilly, Janssen, Kyorin, Nippon Kayaku, Novartis, Ono Pharmaceutical Company, MSD, Pfizer, Taiho, and Takeda Pharmaceutical Company, personal fees from Boehringer Ingelheim and Celtrion, and grants from Kissei, outside the submitted work. Yasuhiro Fujiwara reports personal fees from AstraZeneca, Chugai, Daiichi Sankyo, Bristol-Myers, SRL, and Santen, outside the submitted work. Kan Yonemori reports personal fees from Pfizer, AstraZeneca, EISAI, Takeda Pharmaceutical Company, Chugai, Ono Pharmaceutical Company, Novartis, and Daiichi Sankyo, outside the submitted work. All remaining authors declare no potential conflicts of interest.
: This study was approved by the institutional review board of the National Cancer Center (Tokyo, Japan) (No.214–092).
: The need for informed consent was waived because of the retrospective nature of the study.